menu
    • menu
    [{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"PassPort Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort Technologies \/ Inapplicable"},{"orgOrder":0,"company":"PassPort Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zolmitriptan","moa":"5-HT1D-alpha receptor","graph1":"Neurology","graph2":"Phase I","graph3":"PassPort Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Transdermal Patch","sponsorNew":"PassPort Technologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PassPort Technologies \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by PassPort Technologies

    Menu

    PassPort Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            PassPort Technologies

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            PassPort Technologies

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PassPort Reports Positive Interim Phase 1 Results for Zolmitriptan

                            Details : Zolmitriptan PassPort (zolmitriptan) is a 5-HT1D/5-HT1B binder, small molecule drug, transdermal patch. It is being evaluated in phase 1 clinical trials for the treatment of acute migraine.

                            Product Name : Zolmitriptan PassPort

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 29, 2024

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            PassPort Technologies

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            PassPort Technologies

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PassPort Technologies Initiates Phase 1 of Zolmitriptan Transdermal System for Migraines

                            Details : Zolmitriptan PassPort (zolmitriptan) is a 5-HT1D/5-HT1B binder, small molecule drug, transdermal patch. It is being evaluated in phase 1 clinical trials for the treatment of acute migraine.

                            Product Name : Zolmitriptan PassPort

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 23, 2024

                            Lead Product(s) : Zolmitriptan

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth